Vir’s Hep B Combinations Could Bring Functional Cure To More Patients

Updated Results Will Be EASL Late Breaker

The goal of reaching functional cure rates of up to 30% in hepatitis B now looks realistic, and Vir and GSK and others are racing to find the best combinations of novel and existing treatment options - new results at EASL this week will show how they are faring.

Vir Biotechnology offices San Francisco

Vir Biotechnology is aiming to bring a functional cure to as many as 30% of chronic hepatitis B (HBV) patients via novel drug combinations, and will be looking for its Phase II data to give it an edge on GSK, its main rivals..

The company will have multiple data presentations of its siRNA-based VIR-2218 and monoclonal antibody candidate VIR-3434 at the European Association...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Blood and Clotting

More from Therapeutic Category